ARTICLE | Clinical News
ArQule begins Phase I of ARQ 531 in B cell malignancies
August 17, 2017 11:45 PM UTC
ArQule Inc. (NASDAQ:ARQL) began a Phase I trial to evaluate once-daily oral ARQ 531 for 4 weeks in patients with relapsed or refractory B cell malignancies.
The trial's dose-escalation first portion will test ARQ 531 at a starting dose of 5 mg to determine a recommended Phase II dose. The second portion will evaluate that dose in expansion cohorts for specific malignancies, including a cohort of patients with the C481S Bruton’s tyrosine kinase (Btk) mutation. ArQule expects to enroll up to 120 patients overall...
BCIQ Company Profiles
BCIQ Target Profiles